Comparative effectiveness of ductal carcinoma in situ management and the roles of margins and surgeons
- PMID: 21200025
- PMCID: PMC3022620
- DOI: 10.1093/jnci/djq499
Comparative effectiveness of ductal carcinoma in situ management and the roles of margins and surgeons
Abstract
Background: The high incidence of ductal carcinoma in situ (DCIS) and variations in its treatment motivate inquiry into the comparative effectiveness of treatment options. Few such comparative effectiveness studies of DCIS, however, have been performed with detailed information on clinical and treatment attributes.
Methods: We collected detailed clinical, nonclinical, pathological, treatment, and long-term outcomes data from multiple medical records of 994 women who were diagnosed with DCIS from 1985 through 2000 in Monroe County (New York) and the Henry Ford Health System (Detroit, MI). We used ipsilateral disease-free survival models to characterize the role of treatments (surgery and radiation therapy) and margin status (positive, close [<2 mm], or negative [≥2 mm]) and logistic regression models to characterize the determinants of treatments and margin status, including the role of surgeons. All statistical tests were two-sided.
Results: Treatments and margin status were statistically significant and strong predictors of long-term disease-free survival, but results varied substantially by surgeon. This variation by surgeon accounted for 15%-35% of subsequent ipsilateral 5-year recurrence rates and for 13%-30% of 10-year recurrence rates. The overall differences in predicted 5-year disease-free survival rates for mastectomy (0.993), breast-conserving surgery with radiation therapy (0.945), and breast-conserving surgery without radiation therapy (0.824) were statistically significant (P(diff) < .001 for each of the differences). Similarly, each of the differences at 10 years was statistically significant (P < .001).
Conclusions: Our work demonstrates the contributions of treatments and margin status to long-term ipsilateral disease-free survival and the link between surgeons and these key measures of care. Although variation by surgeon could be generated by patients' preferences, the extent of variation and its contribution to long-term health outcomes are troubling. Further work is required to determine why women with positive margins receive no additional treatment and why margin status and receipt of radiation therapy vary by surgeon.
Figures
Comment in
-
Random physician effect and comparative effectiveness of treatment for ductal carcinoma in situ.J Natl Cancer Inst. 2011 Jan 19;103(2):81-2. doi: 10.1093/jnci/djq511. Epub 2011 Jan 3. J Natl Cancer Inst. 2011. PMID: 21200026 No abstract available.
Similar articles
-
Random physician effect and comparative effectiveness of treatment for ductal carcinoma in situ.J Natl Cancer Inst. 2011 Jan 19;103(2):81-2. doi: 10.1093/jnci/djq511. Epub 2011 Jan 3. J Natl Cancer Inst. 2011. PMID: 21200026 No abstract available.
-
The impact of a focally positive resection margin on the local control in patients treated with breast-conserving therapy.Jpn J Clin Oncol. 2011 May;41(5):600-8. doi: 10.1093/jjco/hyr018. Epub 2011 Feb 24. Jpn J Clin Oncol. 2011. PMID: 21355001
-
Importance of Surgical Margin Status in Ductal Carcinoma In Situ.Clin Breast Cancer. 2016 Aug;16(4):312-8. doi: 10.1016/j.clbc.2016.02.002. Epub 2016 Feb 12. Clin Breast Cancer. 2016. PMID: 26952595
-
Network meta-analysis of margin threshold for women with ductal carcinoma in situ.J Natl Cancer Inst. 2012 Apr 4;104(7):507-16. doi: 10.1093/jnci/djs142. Epub 2012 Mar 22. J Natl Cancer Inst. 2012. PMID: 22440677 Free PMC article. Review.
-
The Association of Surgical Margins and Local Recurrence in Women with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy: A Meta-Analysis.Ann Surg Oncol. 2016 Nov;23(12):3811-3821. doi: 10.1245/s10434-016-5446-2. Epub 2016 Aug 15. Ann Surg Oncol. 2016. PMID: 27527715 Free PMC article. Review.
Cited by
-
Radiological Underestimation of Tumor Size as a Relevant Risk Factor for Positive Margin Rate in Breast-Conserving Therapy of Pure Ductal Carcinoma In Situ (DCIS).Cancers (Basel). 2022 May 11;14(10):2367. doi: 10.3390/cancers14102367. Cancers (Basel). 2022. PMID: 35625972 Free PMC article.
-
Intraoperative Specimen Ultrasonography: Is It a Reliable Tool for Margin Assessment Following Breast Conservation Surgery for Breast Carcinoma?Cureus. 2021 Jun 21;13(6):e15806. doi: 10.7759/cureus.15806. Cureus. 2021. PMID: 34178555 Free PMC article.
-
Time-varying risks of second events following a DCIS diagnosis in the population-based Vermont DCIS cohort.Breast Cancer Res Treat. 2019 Feb;174(1):227-235. doi: 10.1007/s10549-018-5048-8. Epub 2018 Nov 17. Breast Cancer Res Treat. 2019. PMID: 30448897 Free PMC article.
-
Evaluation of intraductal delivery of poly(ethylene glycol)-doxorubicin conjugate nanocarriers for the treatment of ductal carcinoma in situ (DCIS)-like lesions in rats.J Interdiscip Nanomed. 2018 Oct 15;3(3):146-159. doi: 10.1002/jin2.51. eCollection 2018 Sep. J Interdiscip Nanomed. 2018. PMID: 30443411 Free PMC article.
-
Comparative Effectiveness of Surgical Options for Patients with Ductal Carcinoma In Situ: An Instrumental Variable Approach.Perm J. 2018;22:17-132. doi: 10.7812/TPP/17-132. Perm J. 2018. PMID: 30028673 Free PMC article.
References
-
- Initial National Priorities for Comparative Effectiveness Research. Washington, DC: National Academies Press; 2009.
-
- Morrow M, Harris J. Ductal carcinoma in situ and microinvasive carcinoma. In: Harris J, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the Breast. 4th ed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams and Wilkins; 2010. pp. 349–362.
-
- Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353(9169):1993–2000. - PubMed
-
- Rakovitch E, Pignol JP, Chartier C, et al. The management of ductal carcinoma in situ of the breast: a screened population-based analysis. Breast Cancer Res Treat. 2007;101(3):335–347. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
